In contrast, Wang et al. demonstrated that cytoreduction significantly improved the OS rate (62.2% vs. 20.0%, p = 0.013) in MDS-AML patients but not in MDS-EB2 patients (59.2% vs. 62.9%, p = 0.991) [47]. The gene discussed is MAPRE2; the disease is myelodysplastic syndrome.